Editorial
Published on 17 Oct 2022
Editorial: Pulmonary fibrosis: One manifestation, various diseases
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1027332
- 3,442 views
- 13 citations
Type at least 3 characters
673 articles
articles
Original Research
Published on 14 Oct 2022
World Health Organization (WHO) International Classification of Functioning, Disability and Health (ICF) Core Set Development for Interstitial Lung Disease
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.979788
- 12,148 views
- 461 citations
Original Research
Published on 11 Oct 2022
Small airway dysfunction in idiopathic pulmonary fibrosis
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1025814
- 3,851 views
- 13 citations
Original Research
Published on 11 Oct 2022
In vitro neutrophil migration is associated with inhaled corticosteroid treatment and serum cytokines in pediatric asthma
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1021317
- 4,456 views
- 1 citation
Review
Published on 11 Oct 2022
Gene therapy for cystic fibrosis: Challenges and prospects
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1015926
- 41,925 views
- 38 citations
Review
Published on 10 Oct 2022
Drugs for the prevention and treatment of COVID-19 and its complications: An update on what we learned in the past 2 years
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.987816
- 10,403 views
- 13 citations
Original Research
Published on 06 Oct 2022
Capsaicin suppresses ciliary function, while inducing permeability in bronchial epithelial cell cultures of COPD patients
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.996046
- 5,142 views
- 1 citation
Review
Published on 05 Oct 2022
Nebulized corticosteroids versus systemic corticosteroids for patients with acute exacerbation of chronic obstructive pulmonary disease: A systematic review and meta-analysis comparing the benefits and harms reported by observational studies and randomized controlled trials
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.966637
- 6,219 views
- 1 citation
Original Research
Published on 03 Oct 2022
A-Kinase Anchor Protein 1 deficiency causes mitochondrial dysfunction in mouse model of hyperoxia induced acute lung injury
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.980723
- 5,895 views
- 19 citations
Original Research
Published on 30 Sep 2022
The gut-lung axis: Gut microbiota changes associated with pulmonary fibrosis in mouse models induced by bleomycin
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.985223
- 8,202 views
- 23 citations
Original Research
Published on 29 Sep 2022
Potential therapeutic strategies for quercetin targeting critical pathological mechanisms associated with colon adenocarcinoma and COVID-19
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.988153
- 3,949 views
- 5 citations
Original Research
Published on 28 Sep 2022
Safety and efficacy of p38 mitogen-activated protein kinase inhibitors (MAPKIs) in COPD
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.950035
- 3,733 views
- 7 citations
Original Research
Published on 28 Sep 2022
L-cysteine methyl ester overcomes the deleterious effects of morphine on ventilatory parameters and arterial blood-gas chemistry in unanesthetized rats
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.968378
- 4,024 views
- 19 citations
Original Research
Published on 27 Sep 2022
Hydroxychloroquine, azithromycin and methylprednisolone and in hospital survival in severe COVID-19 pneumonia
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.935370
- 5,360 views
- 1 citation
Original Research
Published on 27 Sep 2022
Effect of pulmonary rehabilitation on heart rate recovery in adult individuals with asthma or chronic obstructive pulmonary disease
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.956549
- 3,779 views
- 1 citation
Original Research
Published on 26 Sep 2022
Vegetable glycerin e-cigarette aerosols cause airway inflammation and ion channel dysfunction
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1012723
- 16,207 views
- 34 citations
Opinion
Published on 23 Sep 2022
The application of antimicrobials in VAP patients requiring ECMO supportive treatment
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.918175
- 2,860 views
Review
Published on 16 Sep 2022
Targeting non-coding RNA H19: A potential therapeutic approach in pulmonary diseases
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.978151
- 5,105 views
- 10 citations
Original Research
Published on 16 Sep 2022
Type IV collagen reduces MUC5AC secretion in the lungs of ovalbumin-sensitized mice
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.851374
- 4,039 views
- 5 citations
Original Research
Published on 12 Sep 2022
IL-9 neutralizing antibody suppresses allergic inflammation in ovalbumin-induced allergic rhinitis mouse model
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.935943
- 6,888 views
- 13 citations
Original Research
Published on 07 Sep 2022
Smoking status impacts treatment efficacy in smoke-induced lung inflammation: A pre-clinical study
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.971238
- 2,916 views
Original Research
Published on 07 Sep 2022
ED50 value of remifentanil in inhibiting coughing during extubation in children with snoring
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.965354
- 3,030 views
- 2 citations
Review
Published on 07 Sep 2022
Toll-like receptor (TLRs) agonists and antagonists for COVID-19 treatments
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.989664
- 10,832 views
- 58 citations
Original Research
Published on 06 Sep 2022
Muscarinic receptor M3 activation promotes fibrocytes contraction
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.939780
- 4,885 views
- 7 citations